Navigation Links
Vaccine patent portfolio licensed from UK Ministry of Defence
Date:2/19/2009

TORONTO, Feb. 19 /PRNewswire/ - Defyrus Inc. today announced the signing an exclusive, worldwide license to a patent portfolio created by the United Kingdom's Defence Science and Technology Laboratory (Dstl) and licensed by Ploughshare Innovation Ltd, Dstl's commercialization company. These patents form the intellectual property foundation of the Company's vaccine product development programs. Defyrus and Ploughshare Innovation Ltd plan to expand their commercial interaction in 2009 to include preclinical safety and efficacy studies as part of the Company's vaccine development program. The commercial terms of the license were not disclosed.

The licensed technology of 27 issued & pending international patents, describes the production of multi-valent vaccines for the treatment of alpha-viral infections resulting from bioterrorism or endemic disease. These highly infectious, mosquito-borne encephalitis viruses pose a serious risk to people and livestock for which no vaccine or therapy exists.

"Dstl has pioneered the investigation of effective medical countermeasures (e.g. vaccines and drugs) for the treatment of a number of important biological diseases that are potential biological warfare threats. Their unique approach to vaccine development and compelling animal efficacy data for viral encephalitis made this license attractive" commented Dr. Jeffrey D. Turner, President & CEO of Defyrus, "We see tremendous synergy in levering investor capital with successful Government R&D programs to drive cost-effective, rapid drug development forward. Improving our capability to respond to viral threats from endemic disease or biological warfare is our mission and represents a significant contribution to protecting the international community from dangerous pathogens".

"Defyrus' business model has the hallmark of a true public-private collaboration. In licensing Dstl's technology to Defyrus, whose management team have a proven track record in vaccine development, Ploughshare expects that Dstl's pioneering work can be rapidly translated into vaccines that are available for both the public health markets in the developing world, as well as the North American and European defence markets" stated Andy Tulloch, Chief Executive Officer Ploughshare Innovations. "We look forward to expanding our interactions with Defyrus in the years to come" added Dr. David Harris, Head of Technology Transfer at Dstl.

About Defyrus

Defyrus is a private, life sciences biodefence company that collaborates with domestic and international military R&D partners to develop a range of therapeutics as medical countermeasures for civilians and military personnel. www.defyrus.com

About Ploughshare Innovations & Dstl

Ploughshare is wholly owned by the United Kingdom's Secretary of State for Defence and facilitates the commercialization of defence technologies arising from Dstl. Dstl is an agency of the UK's Ministry of Defence (MoD), existing to supply the very best, impartial, scientific and technical research and advice to the MoD and other Government Departments. Dstl houses one of the largest groups of scientists and engineers (3,500-strong work force) in public service in the UK and supports procurement decisions, defence policy-making and operations. www.ploughshareinnovations.com & www.dstl.gov.uk


'/>"/>
SOURCE Defyrus Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... NY (PRWEB) , ... December 07, 2016 , ... A. ... business owners and families throughout the Five Boroughs, is launching a charity drive to ... works to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu ... fully redesigned website, which launched October 17, 2016, features comprehensive information regarding a ... easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... condemning "scam operations" carried out by unethical locksmith companies and is urging Search ... a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take advantage ...
(Date:12/7/2016)... ... 07, 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo ... CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. ... select from a variety of flip book animations. In Addition, users can modify each ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
(Date:12/7/2016)... 2016 Global Pulmonary Drugs Market: ... the current as well as future prospects of ... include companies and intermediaries engaged in the manufacture ... combinations as well as new entrants planning to ... executive summary along with a market snapshot providing ...
(Date:12/7/2016)... DIEGO , Dec. 7, 2016   Arena ... announced that it has completed enrollment in the ralinepag ... receptor agonist targeting the prostacyclin pathway for the treatment ... 60 patients at sites globally. "This marks ... is evidence of our strategic focus on our pipeline," ...
Breaking Medicine Technology: